Skip to main content
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems
  • Log in
  • My alerts
  • My Cart

Main menu

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
  • ASM
    • Antimicrobial Agents and Chemotherapy
    • Applied and Environmental Microbiology
    • Clinical Microbiology Reviews
    • Clinical and Vaccine Immunology
    • EcoSal Plus
    • Eukaryotic Cell
    • Infection and Immunity
    • Journal of Bacteriology
    • Journal of Clinical Microbiology
    • Journal of Microbiology & Biology Education
    • Journal of Virology
    • mBio
    • Microbiology and Molecular Biology Reviews
    • Microbiology Resource Announcements
    • Microbiology Spectrum
    • Molecular and Cellular Biology
    • mSphere
    • mSystems

User menu

  • Log in
  • My alerts
  • My Cart

Search

  • Advanced search
Antimicrobial Agents and Chemotherapy
publisher-logosite-logo

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Accepted Manuscripts
    • COVID-19 Special Collection
    • Archive
    • Minireviews
  • For Authors
    • Submit a Manuscript
    • Scope
    • Editorial Policy
    • Submission, Review, & Publication Processes
    • Organization and Format
    • Errata, Author Corrections, Retractions
    • Illustrations and Tables
    • Nomenclature
    • Abbreviations and Conventions
    • Publication Fees
    • Ethics Resources and Policies
  • About the Journal
    • About AAC
    • Editor in Chief
    • Editorial Board
    • For Reviewers
    • For the Media
    • For Librarians
    • For Advertisers
    • Alerts
    • AAC Podcast
    • RSS
    • FAQ
  • Subscribe
    • Members
    • Institutions
Mechanisms of Resistance

The EmrR Protein Represses the Escherichia coli emrRAB Multidrug Resistance Operon by Directly Binding to Its Promoter Region

A. Xiong, A. Gottman, C. Park, M. Baetens, S. Pandza, A. Matin
A. Xiong
Department of Microbiology and Immunology, Stanford University School of Medicine, Sherman Fairchild D317, Stanford, California 94305
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Gottman
Department of Microbiology and Immunology, Stanford University School of Medicine, Sherman Fairchild D317, Stanford, California 94305
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C. Park
Department of Microbiology and Immunology, Stanford University School of Medicine, Sherman Fairchild D317, Stanford, California 94305
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
M. Baetens
Department of Microbiology and Immunology, Stanford University School of Medicine, Sherman Fairchild D317, Stanford, California 94305
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
S. Pandza
Department of Microbiology and Immunology, Stanford University School of Medicine, Sherman Fairchild D317, Stanford, California 94305
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A. Matin
Department of Microbiology and Immunology, Stanford University School of Medicine, Sherman Fairchild D317, Stanford, California 94305
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1128/AAC.44.10.2905-2907.2000
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

EmrR negatively regulates the transcription of the multidrug resistance pump-encoding operon, emrRAB, by binding to its regulatory region. The binding site spans the promoter and the downstream sequence up to the transcriptional start site of the operon. Structurally unrelated drugs that induce the pump interfere with this binding.

Bacterial antibiotic resistance is a well-recognized threat to public health. Particularly serious aspects of this phenomenon are the multidrug resistance (MDR) mechanisms that enable bacteria to extrude structurally unrelated antimicrobial agents. Several classes of MDR pumps are known. They appear to have evolved independently several times by recruiting, in some cases at least, preexisting pumps with unrelated functions. As this recruitment can result from relatively minor alterations in the amino acid sequence (5, 11), MDR has the potential of quickly compromising the effectiveness also of new antimicrobial agents.

We have been studying the emrRAB operon-encoded MDR mechanism that can extrude, using proton motive force, several structurally unrelated drugs from Escherichia coli, e.g., protonophores and the antibiotics thiolactomycin and nalidixic acid (NA). The EmrB protein pumps the drugs across the cytoplasmic membrane; EmrA probably facilitates passage through the periplasm; and a third, as yet unidentified protein transports it through the outer membrane (7, 8, 10, 11). The pump is induced by a variety of structurally unrelated drugs, many of which are also its substrates (7, 8).

The emrRAB operon, which has a ς70-type promoter, is negatively regulated by the product of one of its own genes, namely, emrR (8). We postulated that EmrR repression is due to its binding to the promoter of the operon and that this binding is antagonized by drugs that induce the EmrAB pump (6, 8). Here we present direct evidence for this postulate, using gel mobility shift (GMS) assays; further, using footprinting, we have delineated the region of the emrRAB promoter to which EmrR binds.

The regulatory region of the emrRAB operon and theemrR gene were cloned by PCR, using the E. coliK12 Δlac genomic DNA as template and appropriate primers based on previously determined sequences (8). The sequence of the PCR products was determined to ensure lack of mismatches. The cloned regulatory region consisted of 244 nucleotides (nt), spanning 152 nt upstream and 74 nt downstream of the emrRtranslational start site. It was cloned in pUC18 plasmid (12) and is heretofore referred to as the probe DNA. For labeling, [α-33P]dCTP and the Klenow fragment filling-in reaction were used. The emrR gene was subcloned in pET-28a(+) vector (Novagen, Madison, Wis.), and EmrR was overexpressed in E. coli B834(DE3) by isopropyl-β-d-thiogalactopyranoside (1 mM) induction. The protein was purified according to the manufacturer's protocol, using an Ni2+ column and elution with imidazole buffer.

GMS was performed as described (9) using the following reaction mixture (total volume, 20 μl): 1 μg of bovine serum albumin, 1 μg of sheared calf thymus DNA, and various concentrations of EmrR protein (Fig. 1) in 1× GMS buffer [20 mM HEPES (pH 7.6), 1 mM EDTA, 10 mM (NH4)2SO4, 1 mM dithiothreitol, 30 mM KCl, and 0.2% Tween 20]. After 15 min of incubation (25°C), 0.2 ng of labeled probe DNA was added, and the mixture was further incubated for 20 min. Ten microliters of the individual mixtures along with loading buffer (9) were applied to nondenaturing polyacrylamide gels. Following electrophoresis, the gels were dried and the DNA-protein complexes were visualized by autoradiography. Excess calf thymus DNA was included in reaction mixtures to detect specific interaction with the probe DNA.

Fig. 1.
  • Open in new tab
  • Download powerpoint
Fig. 1.

GMS analysis to determine interaction of the EmrR protein with the regulatory region (probe) of the emrRABoperon. Lanes 2 to 4, labeled probe, plus specified EmrR concentrations; lanes 5 to 7, labeled probe plus indicated concentrations of nonlabeled probe DNA and EmrR; lane 1, control (labeled probe without EmrR).

To determine the effect of EmrAB pump inducers on the probe DNA GMS (Fig. 2), 0.4 μg of EmrR was used. Reaction mixtures showing EmrR binding to the promoter region (Fig. 1) were incubated in the presence of different indicated inducers at different concentrations (Fig. 2) prior to electrophoresis.

Fig. 2.
  • Open in new tab
  • Download powerpoint
Fig. 2.

GMS analysis of the effect of the EmrAB inducers on EmrR binding to the emrRAB promoter region. Controls containing the labeled probe DNA without EmrR (lane 1) or with 0.4 μg of EmrR, without the inducers (lane 2), are also shown.

To determine the binding site of EmrR on the probe DNA, footprinting was performed, using the DNase I protection assay (4). The labeled probe was incubated (in GMS buffer [total volume, 20 μL; 25°C]) with different EmrR concentrations (Fig.3). After 20 min, 1 U of DNase I was added, and incubation continued for 1 min.

Fig. 3.
  • Open in new tab
  • Download powerpoint
Fig. 3.

Footprinting of the EmrR binding site on theemrRAB promoter region. Lanes T, G, C, and A, represent the dideoxy sequencing ladder of the emrRAB promoter region used in the assay. Lane 1, probe DNA without EmrR; lanes 2 to 4, same as lane 1, but with 0.1, 0.2, or 0.4 μg of EmrR protein, respectively. The protected sequence is shown, and the following are indicated: the −35 (partial) and −10 regions (8) (shaded), the transcriptional start site (horizontal arrow), and the imperfect 9-3-9 inverted repeat (vertical arrows).

EmrR binds specifically to the emrRAB promoter region.Purification of EmrR resulted in a single band of 24 kDa on sodium dodecyl sulfate-polyacrylamide gels (not shown). This is in good agreement with the calculated molecular mass of EmrR (20.6 kDa [8]) plus the histidine tag. EmrR retarded migration of the probe in a concentration-dependent manner, indicating that it binds to this DNA (Fig. 1, lanes 2 to 4). To determine specificity of the binding, the above reaction was performed in the presence of a 1-, 5-, or 10-fold excess of unlabeled probe; it competed with the labeled probe for EmrR binding (Fig. 1, lanes 5 to 7). Thus, EmrR binds specifically to the probe DNA containing the emrRABregulatory region. EmrR contains a helix-turn-helix motif (in the region of amino acids 87 to 121), which is consistent with this result. GMS experiments using crude extracts of E. coli B834(DE3) overproducing EmrR without the histidine tag gave similar results (data not shown).

Inducers of the EmrAB pump antagonize EmrR binding.The effect of the EmrAB pump inducers (7, 8) carbonyl cyanidem-chlorophenyldrazone (CCCP), 2,4-dinitrophenol, tetrachlorosalicylanilide (TCS), and NA on EmrR binding to the probe was determined by performing GMS in the presence of the individual inducers. All interfered with the binding (Fig. 2, lanes 3 to 10). CCCP and TCS were more effective than 2,4-dinitrophenol and NA, as they completely inhibited the promoter-repressor interaction at 25 μM concentration, as opposed to 50 μM concentrations required by the latter drugs. This is consistent with the in vivo results (8) that CCCP and TCS are more-effective inducers of the pump.

EmrR binding site includes transcriptional start site of the operon.Sequencing of the DNA protected in the footprinting assay showed that it extended from half of the −35 sequence of theemrRAB promoter to the transcriptional start site of the operon (Fig. 3). An imperfect inverted repeat (CTGTCGTTA-CTA-TATCGGCTG) was present in this region.

The above results confirm our postulate regarding EmrR andemrRAB regulatory region interaction (6, 8). While this work was in progress, Brooun et al. (2) reported that certain inducers of the EmrAB pump interact with the EmrR protein; the results reported here are consistent with their finding. Thus, EmrR negatively regulates the emrRAB operon by directly binding to its regulatory region. The pump inducers interact with EmrR, rendering it incapable of binding to this region. Other MDR pump regulators, e.g., BmrR (1) and QacR (3), also interact with effectors and regulatory regions. BmrR binds to its effectors by its C-terminal domain, whose high-resolution structure shows that its binding site can accommodate a broad range of substrates (13). The wide substrate range of EmrR probably also results from a similar binding site architecture. This possibility can now be experimentally tested, as EmrR has recently been crystallized (2). Elucidation of mechanisms underlying regulator interactions with MDR-encoding operons and their effectors will help combat MDR.

ACKNOWLEDGMENTS

This work was supported by a grant from the Office of Technology Licensing, Stanford University to A.M. M.B., S.P., and A.X. were supported by a Dean's fellowship from the Stanford University School of Medicine; M.B. and S.P. received further support from a NATO postdoctoral fellowship and NIH training grant NRSA 5T32 AI0732801, respectively.

We thank John Cha for assistance in some of the experiments.

FOOTNOTES

    • Received 27 April 2000.
    • Returned for modification 13 June 2000.
    • Accepted 26 June 2000.
  • Copyright © 2000 American Society for Microbiology

REFERENCES

  1. 1.↵
    1. Ahmed M.,
    2. Borsch C. M.,
    3. Taylor S. S.,
    4. Vazquez-Laslop N.,
    5. Neyfakh A. A.
    A protein that activates expression of a multidrug efflux transporter upon binding the transporter substrates. J. Biol. Chem. 269 1994 28506 28513
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Brooun A.,
    2. Tomashek J. J.,
    3. Lewis K.
    Purification and ligand binding of EmrR, a regulator of a multidrug transporter. J. Bacteriol. 181 1999 5131 5133
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Grkovic S.,
    2. Brown M. H.,
    3. Roberts N. J.,
    4. Paulsen I. T.,
    5. Skurray R. A.
    QacR is a repressor protein that regulates expression of the Staphylococcus aureus multidrug efflux pump QacA. J. Biol. Chem. 273 1998 18665 18673
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Leblanc B.,
    2. Moss T.
    DNase I footprinting DNA-protein interactions: principles and protocols. Kneale G. G. 1994 1 10Methods in molecular biology. Humana Press, Totawa, N.J.
  5. 5.↵
    1. Lewis K.
    Multidrug resistance: versatile drug sensors of bacterial cells. Curr. Biol. 9 1999 R403 R407
    OpenUrlCrossRefPubMedWeb of Science
  6. 6.↵
    1. Lomovskaya O.,
    2. Kawai F.,
    3. Matin A.
    Differential regulation of the mcb and emr operons of Escherichia coli: role of mcb in multidrug resistance. Antimicrob. Agents Chemother. 40 1996 1050 1052
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Lomovskaya O.,
    2. Lewis K.
    Emr, an Escherichia coli locus for multidrug resistance. Proc. Natl. Acad. Sci. USA 89 1992 8938 8942
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Lomovskaya O.,
    2. Lewis K.,
    3. Matin A.
    EmrR is a negative regulator of the Escherichia coli multidrug resistance pump EmrAB. J. Bacteriol. 177 1995 2328 2334
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. Martin R. G.,
    2. Rosner J. L.
    Binding of purified multiple antibiotic-resistance repressor protein (MarR) to mar operator sequences. Proc. Natl. Acad. Sci. USA 92 1995 5456 5460
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Pao S. S.,
    2. Paulsen I. T.,
    3. Saier M. H. Jr.
    Major facilitator superfamily. Microbiol. Mol. Biol. Rev. 62 1998 1 34
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Paulsen I. T.,
    2. Brown M. H.,
    3. Skurray R. A.
    Proton-dependent multidrug efflux systems. Microbiol. Rev. 60 1996 575 608
    OpenUrlAbstract/FREE Full Text
  12. 12.↵
    1. Yanisch-Perron C.,
    2. Vieira J.,
    3. Messing J.
    Improved M13 phage cloning vectors and host strains: nucleotide sequences of the M13mp18 and pUC19 vector. Gene 33 1985 103 119
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    1. Zheleznova E. E.,
    2. Markham P. N.,
    3. Neyfakh A. A.,
    4. Brennan R. G.
    Structural basis of multidrug recognition by BmrR, a transcription activator of a multidrug transporter. Cell 96 1999 353 362
    OpenUrlCrossRefPubMedWeb of Science
View Abstract
PreviousNext
Back to top
Download PDF
Citation Tools
The EmrR Protein Represses the Escherichia coli emrRAB Multidrug Resistance Operon by Directly Binding to Its Promoter Region
A. Xiong, A. Gottman, C. Park, M. Baetens, S. Pandza, A. Matin
Antimicrobial Agents and Chemotherapy Oct 2000, 44 (10) 2905-2907; DOI: 10.1128/AAC.44.10.2905-2907.2000

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Print

Alerts
Sign In to Email Alerts with your Email Address
Email

Thank you for sharing this Antimicrobial Agents and Chemotherapy article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The EmrR Protein Represses the Escherichia coli emrRAB Multidrug Resistance Operon by Directly Binding to Its Promoter Region
(Your Name) has forwarded a page to you from Antimicrobial Agents and Chemotherapy
(Your Name) thought you would be interested in this article in Antimicrobial Agents and Chemotherapy.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The EmrR Protein Represses the Escherichia coli emrRAB Multidrug Resistance Operon by Directly Binding to Its Promoter Region
A. Xiong, A. Gottman, C. Park, M. Baetens, S. Pandza, A. Matin
Antimicrobial Agents and Chemotherapy Oct 2000, 44 (10) 2905-2907; DOI: 10.1128/AAC.44.10.2905-2907.2000
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Top
  • Article
    • ABSTRACT
    • ACKNOWLEDGMENTS
    • FOOTNOTES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

KEYWORDS

Bacterial Proteins
Escherichia coli
Escherichia coli Proteins
Gene Expression Regulation, Bacterial
Genes, Bacterial
Promoter Regions, Genetic
Repressor Proteins
transcription factors

Related Articles

Cited By...

About

  • About AAC
  • Editor in Chief
  • Editorial Board
  • Policies
  • For Reviewers
  • For the Media
  • For Librarians
  • For Advertisers
  • Alerts
  • AAC Podcast
  • RSS
  • FAQ
  • Permissions
  • Journal Announcements

Authors

  • ASM Author Center
  • Submit a Manuscript
  • Article Types
  • Ethics
  • Contact Us

Follow #AACJournal

@ASMicrobiology

       

ASM Journals

ASM journals are the most prominent publications in the field, delivering up-to-date and authoritative coverage of both basic and clinical microbiology.

About ASM | Contact Us | Press Room

 

ASM is a member of

Scientific Society Publisher Alliance

 

American Society for Microbiology
1752 N St. NW
Washington, DC 20036
Phone: (202) 737-3600

Copyright © 2021 American Society for Microbiology | Privacy Policy | Website feedback

Print ISSN: 0066-4804; Online ISSN: 1098-6596